PER-001-03已完成未知
Prospective, multicenter, double-blind, randomized study to evaluate the safety and efficacy of BAY 12-8039 (moxifioxacin) 400 mg administered sequentially (intravenously / orally) every 24 hours compared with piperacillin / tazobactam 3.375 grams intravenously every 6 hours, followed of oral suspension of amoxicillin / clavulanic acid 800 mg every 12 hours for the treatment of patients with complicated skin and soft tissue infections.
BAYER S.A.,0 个研究点目标入组 0 人开始时间: 2003年2月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female inpatients> 18 years of age. Women
- •Potentially fertile should have a negative pregnancy test and sexually active women should use an acceptable contraceptive method (hormonal or barrier) while the treatment lasts.
- •Diagnosis of skin and soft tissue infections that can be confirmed or suspected based on a Gram stain.
- •The duration of treatment of skin / soft tissue infection will be
- •at least 7 days
排除标准
- •Patients with uncomplicated skin and soft tissue infections that do not
- •require hospitalization or initial treatment with intravenous antibiotics.
- •Known hypersensitivity to any of the study medications including penicillins and cephalosporins.
- •History of hypersensitivity to multivitamin concentrates for infusion or preexisting hypervitaminosis. Background of phenylketonuria.
- •Pregnant women, breastfeeding or in which pregnancy can not be excluded.
- •Renal insufficiency.
研究者
相似试验
已完成
不适用
Prospective, multicenter, double-blind, randomized, cross-over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidemia in children with persisting proteinuriaISRCTN06912061Genzyme Europe20
进行中（未招募）
1 期
Dose-response study of efficacy and safety of Botulinum toxin type A to treat spasticity of the leg(s) in cerebral palsyower limb spasticity due to cerebral palsyMedDRA version: 17.1Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852EUCTR2012-005054-30-SKMerz Pharmaceuticals GmbH300
进行中（未招募）
1 期
Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacksacute hereditary angioedema attacksMedDRA version: 20.0Level: LLTClassification code: 10075280Term: Hereditary angioedema attack Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080960Term: Hereditary angioedema type II Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080957Term: Hereditary angioedema C1 inhibitor deficiency Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080956Term: Hereditary angioedema type I Class: 10010331CTIS2023-503507-29-00Octapharma Pharmazeutika Produktionsgesellschaft mbH124
进行中（未招募）
1 期
Dose-response study of efficacy and safety of Botulinum toxin type A to treat spasticity of the leg(s) in cerebral palsyEUCTR2012-005054-30-DEMerz Pharmaceuticals GmbH300
尚未招募
4 期
Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of Qufengzhitong capsule in the treatment of rheumatoid arthritisrheumatoid arthritisITMCTR2100005057Guang'anmen Hospital, China Academy of Chinese Medical Sciences